Clinical Trials

View All Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

No search term entered. 359 results shown below.

Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma

[Complete title: A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial]
Principal Investigator: David Maloney, MD, PhD
Study Number: 1409.00
Phase: I/II

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

[Complete title: Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected with HIV-1 Using a Non-Marrow Ablative Conditioning Regimen Containing TBI in Combination with Post-Transplant Immunosuppression with Cyclosporine and Mycophenolate Mofetil]
Principal Investigator: Ann Woolfrey, MD
Study Number: 1410.00
Phase: I

Fludarabine, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

[Complete title: Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 1840.00
Phase: II

Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas

[Complete title: Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells for Patients with Malignant Gliomas]
Principal Investigator: Hans-Peter Kiem, MD
Study Number: 2000.00
Phase: I/II

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

[Complete title: Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-dose TBI and Fludarabine With or Without Campath®]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2007.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

[Complete title: HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning with Low-dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2032.00
Phase: II

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

[Complete title: Low-dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders -- A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2056.00
Phase: II

Nonmyeloablative transplant for severe systemic sclerosis

[Complete title: Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2067.00
Phase: I/II

Gene Therapy for Fanconi Anemia

[Complete title: Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA)]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 2097.00
Phase: I

Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

[Complete title: Allogeneic Hematopoietic Cell Transplantation for Patients with Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2256.00
Phase: II

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

[Complete title: Bortezomib and Vorinostat as Maintenance Therapy after Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2292.00
Phase: II

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

[Complete title: A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2361.00
Phase: I

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

[Complete title: Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2368.00
Phase: NA

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

[Complete title: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 2398.00
Phase: II

Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2430.00
Phase: II

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

[Complete title: A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma]
Principal Investigator: Damian Green, MD
Study Number: 2450.00
Phase: I

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

[Complete title: A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (anti-CD45) Antibody followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2468.00
Phase: I

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

[Complete title: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)]
Principal Investigator: Edward Libby
Study Number: 2477.00
Phase: III

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

[Complete title: AMC PROTOCOL #075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma. A Trial of the AIDS Malignancy Consortium (AMC)]
Principal Investigator: Manoj Menon
Study Number: 2483.00
Phase: I/II

Selecting a Favorable KIR Donor in Unrelated HCT for AML

[Complete title: KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2484.00
Phase: NA

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

[Complete title: Phase I/II Study of Adoptive Immunotherapy with Virus Specific CD8+ T Cells that have been Transduced to Express a WT1-Specific T Cell Receptor for Patients with High Risk or Relapsed AML, MDS, or CML]
Principal Investigator: Daniel Egan
Study Number: 2498.00
Phase: I/II

Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome

[Complete title: A Randomized Phase II Multi-Center Study of Treosulfan, Fludarabine and Low-Dose TBI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)]
Principal Investigator: Joachim Deeg, MD
Study Number: 2524.00
Phase: II

Scleroderma Treatment with Autologous Transplant (STAT) Study

[Complete title: A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2533.00
Phase: II

Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients with AML or Acute Leukemia of Ambiguous Lineage]
Principal Investigator: Ann Dahlberg
Study Number: 2584.00
Phase: Pilot

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

[Complete title: Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma]
Principal Investigator: Aude Chapuis, MD
Study Number: 2586.00
Phase: I

Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

[Complete title: Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2603.00
Phase: II

INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant

[Complete title: INSPIRE for Survivorship after Transplant: A Multicenter Randomized Controlled Trial of an Internet and Social-media Program for Long-term Hematopoietic Cell Transplantation Survivors]
Principal Investigator: Karen Syrjala, PhD
Study Number: 2605.00
Phase: III

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

[Complete title: A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma S/P Autologous Hematopoietic Cell Transplantation]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2620.00
Phase: II

Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

[Complete title: Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality]
Principal Investigator: Roland Walter, MD
Study Number: 2642.00
Phase: Pilot

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

[Complete title: Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion with Cyclophosphamide and Fludarabine For Patients With Metastatic Melanoma]
Principal Investigator: Sylvia Lee, MD
Study Number: 2643.00
Phase: II

Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

[Complete title: Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study]
Principal Investigator: Anna Halpern
Study Number: 2652.00
Phase: I/II

Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

[Complete title: A Phase II Study of Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children]
Principal Investigator: Marie Bleakley, MD
Study Number: 2660.00
Phase: II

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

[Complete title: Initial Cytoreductive Therapy for Myelodysplastic Syndrome prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)]
Principal Investigator: Bart Scott, MD
Study Number: 2661.00
Phase: II

Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

[Complete title: A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD]
Principal Investigator: Marie Bleakley, MD
Study Number: 2684.00
Phase: II

Abatacept as GVHD Prophylaxis Phase 2

[Complete title: Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial]
Principal Investigator: Leslie Kean
Study Number: 2692.00
Phase: Pilot

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

[Complete title: A Pilot Study to Test whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients with Synovial Sarcoma and Myxoid / Round Cell Liposarcoma]
Principal Investigator: Seth Pollack
Study Number: 2705.00
Phase: Pilot

Chronic GVHD Response Measures Validation

[Complete title: Chronic GVHD Response Measures Validation]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2710.00
Phase: NA

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

[Complete title: AMC Protocol #085: A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma]
Principal Investigator: Manoj Menon
Study Number: 2719.00
Phase: I/II

NY-ESO-1-specific T Cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy

[Complete title: A pilot trial of NY-ESO-1-specific T cells in patients with metastatic NY-ESO-1-expressing sarcomas receiving palliative radiation]
Principal Investigator: Seth Pollack
Study Number: 2721.00
Phase: I

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

[Complete title: A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)]
Principal Investigator: Roland Walter, MD
Study Number: 2734.00
Phase: I/II

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer

[Complete title: Combined Targeted Therapies for Triple Negative Advanced Breast Cancer – A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib]
Principal Investigator: Jennifer Specht, MD
Study Number: 6628
Phase: II

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

[Complete title: A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)]
Principal Investigator: Marc Chamberlain, MD
Study Number: 6803
Phase: II

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

[Complete title: Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy]
Principal Investigator: Robert Montgomery, MD
Study Number: 6932
Phase: NA

F-18 FES PET in Measuring Hormone Expression in Patients with Primary, Recurrent or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

[Complete title: Serial [F-18] fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy]
Principal Investigator: Hannah Linden, MD
Study Number: 7184
Phase: NA

Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

[Complete title: The Effect of Antiangiogenic Therapy with Pazopanib Prior to Preoperative Chemotherapy for Subjects with Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging]
Principal Investigator: Darin Davidson
Study Number: 7487
Phase: Pilot

Human Papillomavirus (HPV) or Pap Examination (HOPE) Study

[Complete title: Cytology vs. at Home HPV Screening for Detection of CIN 2,3,CIS]
Principal Investigator: Nancy Kiviat, MD
Study Number: 7489
Phase: NA

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

[Complete title: A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer]
Principal Investigator: Shilpen Patel, MD
Study Number: 7506
Phase: I

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

[Complete title: I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)]
Principal Investigator: Larissa Korde
Study Number: 7518
Phase: II

FLAX FX, A research study of the effects of flaxseed lignans on colon health
Principal Investigator: Johanna Lampe, PhD, RD
Study Number: 7532
Phase: NA

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

[Complete title: Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy with [18F]fluorothymidine (FLT) PET]
Principal Investigator: Hannah Linden, MD
Study Number: 7536
Phase: NA

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

[Complete title: A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy]
Principal Investigator: Evan Yu, MD
Study Number: 7563
Phase: II

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

[Complete title: Quantitative Dynamic PET and MRI and Breast Cancer Therapy]
Principal Investigator: Jennifer Specht, MD
Study Number: 7587
Phase: NA

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 7639
Phase: II

Capecitabine and Celecoxib With or Without Radiation Therapy in Treating Patients With Colorectal Cancer That Is Newly Diagnosed or Previously Treated With Fluorouracil

[Complete title: A Phase II Trial of Maintenance ADAPT Therapy with Capecitabine and Celecoxib in Patients with Metastatic Colorectal Cancer]
Principal Investigator: Edward Lin, MD
Study Number: 7707
Phase: II

18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors

[Complete title: Cellular Proliferation Imaging Using [18F]fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors]
Principal Investigator: Jason Rockhill
Study Number: 7754
Phase: NA

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

[Complete title: A Phase II Study of Weekly ABRAXANE® for Patients with Advanced NSCLC with EGFR Mutations or with Durable Response to an EGFR Tyrosine Kinase Inhibitor following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors]
Principal Investigator: Christina Baik
Study Number: 7755
Phase: II

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

[Complete title: A Phase II Study of Carboplatin, Nab-Paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 7797
Phase: II

Brentuximab Vedotin in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

[Complete title: A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+ Malignancies Refractory to Every > = 3 Week Brentuximab Vedotin]
Principal Investigator: Ajay Gopal, MD
Study Number: 7808
Phase: Pilot

Cabozantinib in Treating Men With Hormone-Resistant Prostate Cancer

[Complete title: A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 7819
Phase: Pilot

Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer

[Complete title: Degarelix Acetate Prior to Radiation Therapy]
Principal Investigator: Robert Montgomery, MD
Study Number: 7846
Phase: Pilot

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT-888 For Patients With Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 7847
Phase: II

Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

[Complete title: Thrombokinetic Studies of Trastuzumab Emtansine]
Principal Investigator: V.K. Gadi, MD, PhD
Study Number: 7900
Phase: I

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (LDTam)

[Complete title: Low-dose Tamoxifen For Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial]
Principal Investigator: Larissa Korde
Study Number: 7908
Phase: II

Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

[Complete title: Feasibility of Outpatient Induction Chemotherapy for Adult Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 7910
Phase: Pilot

revention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

[Complete title: Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer]
Principal Investigator: Larissa Korde
Study Number: 7952
Phase: NA

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

[Complete title: A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients with Bladder Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 8027
Phase: I/II

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

[Complete title: A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 8040
Phase: II

Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

[Complete title: Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)]
Principal Investigator: Hannah Linden, MD
Study Number: 8093
Phase: II

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

[Complete title: MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix]
Principal Investigator: Nina Mayr, MD
Study Number: 8118
Phase: NA

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy

[Complete title: Pulmonary Functional Imaging for Radiation Treatment Planning for Lung Cancer]
Principal Investigator: Jing Zeng
Study Number: 8180
Phase: Pilot

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

[Complete title: Decitabine plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 9019
Phase: II

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

[Complete title: A Phase 2, Multi-Center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma]
Principal Investigator: Andrei Shustov, MD
Study Number: 9023
Phase: II

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

[Complete title: RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy followed by Ipilimumab in Metastatic Melanoma]
Principal Investigator: Ramesh Rengan
Study Number: 9031
Phase: II

JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

[Complete title: JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients with Primary and Secondary Myelofibrosis: A Prospective Study]
Principal Investigator: Rachel Salit
Study Number: 9033
Phase: II

Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling

[Complete title: Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) with Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing]
Principal Investigator: Robert Montgomery, MD
Study Number: 9055
Phase: II

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

[Complete title: A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients with Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)]
Principal Investigator: Ajay Gopal, MD
Study Number: 9111
Phase: I/II

Allo vs. Hypomethylating/Best Supportive Care in MDS

[Complete title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome]
Principal Investigator: Bart Scott, MD
Study Number: 9129
Phase: III

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

[Complete title: A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients]
Principal Investigator: Nora Disis, MD
Study Number: 9140
Phase: I

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Metastatic Sarcoma

[Complete title: A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) with Radiation in Patients with Metastatic Sarcoma]
Principal Investigator: Seth Pollack
Study Number: 9145
Phase: I

Proton Beam Radiation Therapy in Treating Patients With Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy

[Complete title: Definitive Re-Irradiation with Proton Beam Radiotherapy for Patients with Recurrent Thoracic Cancers]
Principal Investigator: Jing Zeng
Study Number: 9148
Phase: Pilot

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

[Complete title: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer]
Principal Investigator: Jennifer Specht, MD
Study Number: 9198
Phase: II

Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

[Complete title: Prevention of Bone Loss after Pediatric Hematopoietic Cell Transplantation]
Principal Investigator: K.Scott Baker
Study Number: 9223
Phase: II

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

[Complete title: Randomized placebo control trial of perioperative gabapentin to reduce total analgesic requirements in patients undergoing radical cystectomy]
Principal Investigator: Jonathan Wright
Study Number: 9274
Phase: II/III

Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse Caregivers

[Complete title: A Pilot Feasibility Study: Taking Care of Her]
Principal Investigator: Frances Lewis
Study Number: 9306
Phase: Pilot

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL)

[Complete title: PARTIQol: Prostate Advance Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer]
Principal Investigator: Jing Zeng
Study Number: 9328
Phase: III

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

[Complete title: The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)]
Principal Investigator: Vivian Oehler, MD
Study Number: 9361
Phase: II

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma

[Complete title: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isoretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS0332
Phase: III

Clinical Database for Sarcoma Patients (Sarcobase)
Principal Investigator: Doug Hawkins, MD
Study Number: CHMC-6009
Phase: NA

Pediatric Bone Tumor Biology Study
Principal Investigator: Doug Hawkins, MD
Study Number: CHRMC-B600
Phase: NA

Bone Marrow Failure Specimen Repository and Specimen Registry
Principal Investigator: Akiko Shimamura, MD, PhD
Study Number: CHRMC-B800
Phase: NA

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

[Complete title: Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma using Autologous T-cells lentivirally transduced to express CD171-specific Chimeric Antigen Receptors]
Principal Investigator: Julie Park, MD
Study Number: ENCIT-01
Phase: I

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

[Complete title: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy]
Principal Investigator: Heidi Gray, MD
Study Number: GOG 0724/ RTOG 0724
Phase: III

HEAL-2 "Health Effects After Leukemia Research Study #2"
Principal Investigator: Eric Chow, MD
Study Number: HEAL-2
Phase: NA

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia (Interfant06)

[Complete title: Interfant 06: International Collaborative Treatment Protocol For Infants Under One Year with Acute Lymphoblastic Leukemia or Biphenotypic Leukemia]
Principal Investigator: Rebecca Gardner, MD
Study Number: Interfant-06

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

[Complete title: Pediatric Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Acute Lymphoblastic Leukemia]
Principal Investigator: Rebecca Gardner, MD
Study Number: PLAT-02
Phase: I/II

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma

[Complete title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients with Previously Treated, Incurable Ewing Sarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: SC-6015
Phase: I

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

[Complete title: A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients with Recurrent or Progressive Intracranial Germ Cell Tumors]
Principal Investigator: Sarah Leary
Study Number: SC-9002
Phase: II

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

[Complete title: Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas]
Principal Investigator: Sarah Leary
Study Number: SC-9005
Phase: II

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors (SEED)

[Complete title: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients with Refractory or Recurrent Brain Tumors]
Principal Investigator: Sarah Leary
Study Number: SC-9006
Phase: Pilot

DNA Methylation in Pediatric Rhabdomyosarcoma
Principal Investigator: Doug Hawkins, MD
Study Number: SC-B603

Construction of a Metastatic Osteosarcoma Tissue Microarray
Principal Investigator: Doug Hawkins, MD
Study Number: SC-B604

Analysis of Surgical Margins and Local Recurrence Risk in Patients with Osteosarcoma
Principal Investigator: Doug Hawkins, MD
Study Number: SC-B606

Evaluation of microRNAs as novel markers of cardiotoxicity in children undergoing anthracycline therapy for pediatric cancer
Principal Investigator: Kasey Leger, MD
Study Number: SC-B610

Genetic Risk Factors of Ewing Sarcoma
Principal Investigator: Doug Hawkins, MD
Study Number: SC-B611

Exploring Genetic Changes In Pediatric Brain Tumors
Principal Investigator: Sarah Leary
Study Number: SC-B904

Decision-making for the child with relapsed or refractory neuroblastoma
Principal Investigator: Abby Rosenberg
Study Number: SC-N110

Development of the Promoting Resilience in Stress Management in Parents/Caregivers (PRISM-P) intervention: building resilience in caregivers of youth with chronic/serious illness
Principal Investigator: Abby Rosenberg
Study Number: SC-N113

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

[Complete title: Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation - A Multicenter Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 1825.00
Phase: II

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2010.00
Phase: II

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

[Complete title: Hematopoietic Bone Marrow Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After Transplantation]
Principal Investigator: Johnnie Orozco, MD, PhD
Study Number: 2186.00
Phase: II

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2206.00
Phase: II

Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer

[Complete title: Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution after Myeloablative Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected with HIV]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2212.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

[Complete title: A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2230.00
Phase: I/II

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

[Complete title: A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2238.00
Phase: I

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen]
Principal Investigator: Rachel Salit
Study Number: 2239.00
Phase: II

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

[Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2241.00
Phase: II

Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy

[Complete title: High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases]
Principal Investigator: George Georges, MD
Study Number: 2260.00
Phase: II

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2275.00
Phase: II

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

[Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source]
Principal Investigator: Rachel Salit
Study Number: 2372.00
Phase: II

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2448.00
Phase: III

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

[Complete title: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2531.00
Phase: NA

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2546.00
Phase: II

Alpha 1 Anti-Trypsin in Treating Patients With Acute Graft-Versus-Host Disease

[Complete title: Treatment of Steroid Non-responsive Acute GVHD with Alpha 1 Anti-trypsin (AAT). A Phase I/II Study]
Principal Investigator: Joachim Deeg, MD
Study Number: 2571.00
Phase: I/II

Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)

[Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies]
Principal Investigator: Rachel Salit
Study Number: 2580.00
Phase: III

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

[Complete title: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor]
Principal Investigator: David Maloney, MD, PhD
Study Number: 2639.00
Phase: I/II

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

[Complete title: A Study To Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/ Round Cell Liposarcoma using Autologous NY-ESO-1 Specific CD8+ T Cells with Cyclophosphamide Pre-Conditioning but Without the Use of IL-2]
Principal Investigator: Seth Pollack
Study Number: 2720.00
Phase: I

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

[Complete title: Phase I/II study in WT1-expressing non-small cell lung cancer and mesothelioma, comparing cellular adoptive immunotherapy with polyclonal autologous central memory to naïve CD8+ T cells that have been transduced to express a WT1-specific T cell receptor]
Principal Investigator: Sylvia Lee, MD
Study Number: 2727.00
Phase: I/II

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

[Complete title: A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2728.00
Phase: I/II

Cognitive Rehabilitation in Cancer Survivors: A Pilot Study
Principal Investigator: Monique Cherrier, PhD
Study Number: 7279
Phase: NA

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

[Complete title: Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 7674
Phase: II

Reduced Intensity Conditioning for Children and Adults With Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (PIDs) (BMT Clinical Trials Network 1204) (RICHI)

[Complete title: Reduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)]
Principal Investigator: Lauri Burroughs, MD
Study Number: 9027
Phase: II

Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

[Complete title: Protocol AMC-087: Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection]
Principal Investigator: Manoj Menon
Study Number: 9036
Phase: I

Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

[Complete title: Integrating a Telemonitoring Device into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study]
Principal Investigator: Roland Walter, MD
Study Number: 9105
Phase: Pilot

Ibrutinib in Treating Patients With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma

[Complete title: A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 9107
Phase: Pilot

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

[Complete title: A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine]
Principal Investigator: K.Scott Baker
Study Number: 9213
Phase: II

COcoa Supplement and Multivitamin Outcomes Study (COSMOS)

[Complete title: The Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) Trial Protocol]
Principal Investigator: Garnet Anderson, PhD
Study Number: 9214
Phase: NA

Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients With Cancer

[Complete title: Caring for Caregivers: Increasing Cancer Caregiver Wellbeing and Comforting Sensitivity]
Principal Investigator: Linda Ko
Study Number: 9216
Phase: NA

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

[Complete title: AMC 091: Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma]
Principal Investigator: Manoj Menon
Study Number: 9322
Phase: I

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment (HEART)

[Complete title: Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy]
Principal Investigator: Eric Chow, MD
Study Number: ALTE11C2
Phase: NA

Long Term Follow-Up of Patients Previously Entered on Children's Hospital and Regional Medical Center Hematology/Oncology Clinical Trials
Principal Investigator: Debra Friedman, MD
Study Number: CHMC-L001

Childhood Cancer Survivor Study

[Complete title: Childhood Cancer Survivor Study]
Principal Investigator: K.Scott Baker
Study Number: CHMC-M002

DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma

[Complete title: Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study]
Principal Investigator: J. Russell Geyer, MD
Study Number: CHRMC-B901
Phase: Pilot

Fertility Preservation in Pre-pubertal Boys: An Experimental Approach
Principal Investigator: Margarett Shnorhavorian
Study Number: ORCAS-3
Phase: NA

Voices of Children and Adolescents on Phase I or Phase II Cancer Trials
Principal Investigator: Catherine Macpherson, PhD, RN
Study Number: PROMIS III

PD-1 Pathway Protein Expression in Pediatric Cancer
Principal Investigator: Doug Hawkins, MD
Study Number: SC-B609

Prospective Blood Collection for Local Pre-Clinical Studies
Principal Investigator: Rebecca Gardner, MD
Study Number: SC-B801

Seattle Children's Tumor and Tissue Banking Protocol
Principal Investigator: Sarah Leary
Study Number: SC-B802

A Computer-Based Tool to Explore Symptom Clusters in Adolescents with Cancer
Principal Investigator: Catherine Macpherson, PhD, RN
Study Number: SC-N104
Phase: NA

Promoting Resilience during and after Childhood Cancer
Principal Investigator: Abby Rosenberg
Study Number: SC-N107

Resilience in Serious Illness: a pilot feasibility study of the Promoting Resilience in Stress Management (PRISM) Intervention
Principal Investigator: Abby Rosenberg
Study Number: SC-N108

Defining “a good death” for adolescents and young adults with cancer
Principal Investigator: Abby Rosenberg
Study Number: SC-N109
Phase: NA

A Pilot RCT of the PRISM Intervention for AYAs With Cancer

[Complete title: SC-N114: A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Adolescents and Young Adults with Cancer]
Principal Investigator: Abby Rosenberg
Study Number: SC-N114
Phase: Pilot

SC-N115: Resilience in Serious Illness: a pilot feasibility study of the Promoting Resilience in Stress Management for Parents/Caregivers (PRISM-P) Intervention
Principal Investigator: Abby Rosenberg
Study Number: SC-N115
Phase: Pilot

Hypospadias, Indescended Testis, and Testicular Tumors: A Data and Specimen Banking Pilot Study
Principal Investigator: Margarett Shnorhavorian
Study Number: SCH-HUT-1

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

[Complete title: A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies]
Principal Investigator: Todd Cooper
Study Number: TACL 2009-012
Phase: I

Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202)

[Complete title: Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT]
Principal Investigator: John Hansen, MD
Study Number: 2679.00
Phase: NA

Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

[Complete title: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally - Advanced Resected Head and Neck Cancer]
Principal Investigator: George Laramore, MD, PhD
Study Number: 7428
Phase: III

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer

[Complete title: A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer]
Principal Investigator: John Thompson, MD
Study Number: 7637a
Phase: I

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

[Complete title: RTOG 0926 A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging]
Principal Investigator: George Laramore, MD, PhD
Study Number: 7684
Phase: II

Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma

[Complete title: RTOG 0834: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The CATNON Intergroup Trial]
Principal Investigator: George Laramore, MD, PhD
Study Number: 7880
Phase: III

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

[Complete title: RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma]
Principal Investigator: George Laramore, MD, PhD
Study Number: 8024
Phase: II

A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)
Principal Investigator: Evan Yu, MD
Study Number: 8037A
Phase: II

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

[Complete title: RTOG 1010 A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma]
Principal Investigator: George Laramore, MD, PhD
Study Number: 8065
Phase: III

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

[Complete title: A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC)]
Principal Investigator: Paul Nghiem
Study Number: 8269a
Phase: II

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Melanoma

[Complete title: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer]
Principal Investigator: Sylvia Lee, MD
Study Number: 9103A
Phase: I

S1313, Combination Chemotherapy With or Without PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

[Complete title: S1313, A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma]
Principal Investigator: Gabriela Chiorean
Study Number: 9118
Phase: I/II

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

[Complete title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: 9174
Phase: III

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

[Complete title: Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer]
Principal Investigator: Eddie Mendez
Study Number: 9188
Phase: II

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

[Complete title: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer]
Principal Investigator: Heather Cheng
Study Number: 9293
Phase: III

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

[Complete title: A Phase II Study of the Anti-CD22 Recombinant Immunotuxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children with B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation]
Principal Investigator: Ann Woolfrey, MD
Study Number: 9324
Phase: II

Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

[Complete title: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision]
Principal Investigator: Gabriela Chiorean
Study Number: 9412
Phase: II/III

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

[Complete title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Rafael Santana-Davila
Study Number: A081105
Phase: III

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

[Complete title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)]
Principal Investigator: Rafael Santana-Davila
Study Number: A151216
Phase: NA

Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

[Complete title: AALL05B1, A Children's Oncology Group Protocol for the Collecting and Banking of Relapsed Acute Lymphoblastic Leukemias]
Principal Investigator: Doug Hawkins, MD
Study Number: AALL05B1

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

[Complete title: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)]
Principal Investigator: Doug Hawkins, MD
Study Number: AALL08B1

Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

[Complete title: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL).]
Principal Investigator: Doug Hawkins, MD
Study Number: AALL0932
Phase: III

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

[Complete title: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum]
Principal Investigator: Doug Hawkins, MD
Study Number: AALL1131
Phase: III

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

[Complete title: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)]
Principal Investigator: Kasey Leger, MD
Study Number: AALL1231
Phase: III

Study of Blood Samples From Newborns With Down Syndrome

[Complete title: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)]
Principal Investigator: Doug Hawkins, MD
Study Number: AAML08B1
Phase: NA

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

[Complete title: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD]
Principal Investigator: Doug Hawkins, MD
Study Number: AAML1031
Phase: III

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

[Complete title: A Children's Oncology Group Protocol For Collecting And Banking Pediatric Research Specimens Including Rare Tumors]
Principal Investigator: Doug Hawkins, MD
Study Number: ABTR01B1
Phase: NA

Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

[Complete title: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)]
Principal Investigator: Doug Hawkins, MD
Study Number: ACCL0933
Phase: III

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

[Complete title: ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL]
Principal Investigator: Eric Chow, MD
Study Number: ACCL1033
Phase: NA

Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group

[Complete title: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) and Local Data Collection]
Principal Investigator: Doug Hawkins, MD
Study Number: ACCRN07

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

[Complete title: CHRMC Brain Tumor Research Specimen Distribution Protocol including COG-ACNS02B3: A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens]
Principal Investigator: J. Russell Geyer, MD
Study Number: ACNS02B3
Phase: NA

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

[Complete title: Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS0821
Phase: II

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

[Complete title: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS0831
Phase: III

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

[Complete title: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS1123
Phase: II

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma

[Complete title: A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS1221
Phase: II

Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

[Complete title: A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-MET, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma]
Principal Investigator: Julie Park, MD
Study Number: ADVL0912
Phase: I/II

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas. (BOLD 113)

[Complete title: ADVL1314, A Phase 1 Study Of Eribulin Mesylate (E7389, IND #116,292), A Novel Microtubule Targeting Chemotherapeutic Agent In Children With Refractory Or Recurrent Solid Tumors (Excluding CNS), Including Lymphomas]
Principal Investigator: Doug Hawkins, MD
Study Number: ADVL1314
Phase: I

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

[Complete title: ADVL1315, A PHASE 1 STUDY OF THE VEGF RECEPTOR TYROSINE KINASE INHIBITOR AXITINIB (INLYTA, IND# 123101) IN CHILDREN WITH RECURRENT OR REFRACTORY SOLID TUMORS]
Principal Investigator: Julie Park, MD
Study Number: ADVL1315
Phase: I/II

BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

[Complete title: A PHASE 1/ 2 STUDY OF BMN 673 (IND# 121510), AN ORAL POLY(ADP-RIBOSE) POLYMERASE INHIBITOR, PLUS TEMOZOLOMIDE IN CHILDREN WITH REFRACTORY OR RECURRENT MALIGNANCIES]
Principal Investigator: Julie Park, MD
Study Number: ADVL1411
Phase: I/II

Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

[Complete title: A Children’s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens]
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS07B1
Phase: NA

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

[Complete title: A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS1031
Phase: III

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

[Complete title: AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS1221
Phase: II

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

[Complete title: Treatment of Children with All Stages of Hepatoblastoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AHEP0731
Phase: III

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

[Complete title: AHOD1221, A Phase 1/2 Trial of Brentuximab Vedotin (SGN35, IND# 117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AHOD1221

Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma

[Complete title: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents]
Principal Investigator: Doug Hawkins, MD
Study Number: AHOD1331
Phase: III

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

[Complete title: COG-ALTE03N1: Key Adverse Events after Childhood Cancer]
Principal Investigator: K.Scott Baker
Study Number: ALTE03N1
Phase: NA

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

[Complete title: Umbrella Long-term Follow-up Protocol]
Principal Investigator: Doug Hawkins, MD
Study Number: ALTE05N1

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

[Complete title: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer]
Principal Investigator: Doug Hawkins, MD
Study Number: ALTE07C1
Phase: NA

Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

[Complete title: ALTE11C1: Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma]
Principal Investigator: Eric Chow, MD
Study Number: ALTE11C1
Phase: NA

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

[Complete title: Phase III, Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High-Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue]
Principal Investigator: Julie Park, MD
Study Number: ANBL0032
Phase: III

Neuroblastoma Biology Study

[Complete title: Neuroblastoma Biology Studies]
Principal Investigator: Julie Park, MD
Study Number: ANBL00B1
Phase: NA

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

[Complete title: ANBL1232 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study]
Principal Investigator: Julie Park, MD
Study Number: ANBL1232
Phase: III

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

[Complete title: Rare and Cutaneous Non-Hodgkin Lymphoma Registry]
Principal Investigator: Doug Hawkins, MD
Study Number: ANHL04B1
Phase: NA

Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia

[Complete title: Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients]
Principal Investigator: Doug Hawkins, MD
Study Number: ANHL1131
Phase: II/III

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

[Complete title: ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)]
Principal Investigator: Doug Hawkins, MD
Study Number: ANHL12P1

Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

[Complete title: A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens]
Principal Investigator: Doug Hawkins, MD
Study Number: AOST06B1
Phase: NA

Study of Kidney Tumors in Younger Patients

[Complete title: Renal Tumors Classification, Biology, and Banking Study]
Principal Investigator: Doug Hawkins, MD
Study Number: AREN03B2
Phase: NA

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

[Complete title: ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)]
Principal Investigator: Doug Hawkins, MD
Study Number: ARST1321
Phase: II

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

[Complete title: A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant FOLFOX Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: C80702
Phase: III

CYT107 With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: A Phase II Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved Therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC)]
Principal Investigator: Mac Cheever
Study Number: CITN12-03
Phase: II

A Single Arm Trial of Systemic and Subtenon Chemotherapy for Group C/D Intraocular Retinoblastoma
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARET0231
Phase: III

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

[Complete title: A COG Soft Tissue Sarcoma Diagnosis, Biology, and Banking Protocol]
Principal Investigator: Doug Hawkins, MD
Study Number: D9902
Phase: NA

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

[Complete title: Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB ? R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV? R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB ? LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ? LR)]
Principal Investigator: Brian Till, MD
Study Number: E1411
Phase: II

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

[Complete title: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)]
Principal Investigator: Mazyar Shadman
Study Number: E1912
Phase: III

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

[Complete title: Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)]
Principal Investigator: Habib Rahbar
Study Number: E4112
Phase: Pilot

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

[Complete title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein]
Principal Investigator: Rafael Santana-Davila
Study Number: E4512
Phase: III

Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

[Complete title: A Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA , Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy]
Principal Investigator: Heidi Gray, MD
Study Number: GOG 0263
Phase: III

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

[Complete title: A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer (GOG-0281)]
Principal Investigator: Heidi Gray, MD
Study Number: GOG-0281
Phase: II/III

Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA

[Complete title: Long Term Follow up of Patients Previously Entered on Children's Cancer Group clinical Trials]
Principal Investigator: K.Scott Baker
Study Number: LTF-1

Neuroblastoma Biology Study

[Complete title: Neuroblastoma Biology Study]
Principal Investigator: Julie Park, MD
Study Number: NANT 2004-05
Phase: NA

Study of MLN8237 in Combination With Irinotecan and Temozolomide

[Complete title: Phase I/II Study Of MLN8237 In Combination With Irinotecanand Temozolomide For Patients With Relapsed Or Refractory Neuroblastoma]
Principal Investigator: Julie Park, MD
Study Number: NANT 2009-03
Phase: I/II

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

[Complete title: A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma]
Principal Investigator: Julie Park, MD
Study Number: NANT 2011-04
Phase: II

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

[Complete title: N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma]
Principal Investigator: Julie Park, MD
Study Number: NANT 2012-01
Phase: I

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

[Complete title: A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer]
Principal Investigator: Heidi Gray, MD
Study Number: NRG-GY002
Phase: II

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

[Complete title: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy]
Principal Investigator: Janice Kim, MD
Study Number: NSABP B-51 / RTOG 1304
Phase: III

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

[Complete title: Phase I study of CDK 4-6 inhibitor PD-0332991 in children with recurrent, progressive or refractory central nervous system tumors]
Principal Investigator: Sarah Leary
Study Number: PBTC-042
Phase: I

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

[Complete title: Phase II Study of everolimus for recurrent or progressive low-grade gliomas in children]
Principal Investigator: Sarah Leary
Study Number: PNOC001
Phase: II

Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas

[Complete title: Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E- or BRAF Ins T mutant Brain Tumors]
Principal Investigator: Sarah Leary
Study Number: PNOC002
Phase: Pilot

Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer

[Complete title: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck]
Principal Investigator: Tina Rodriguez
Study Number: RTOG 1216
Phase: II/III

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

[Complete title: SWOG: A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)]
Principal Investigator: Oliver Press, MD, PhD
Study Number: S1001
Phase: II

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

[Complete title: A Phase III, Randomized Clinical Trial Of Standard Adjuvant Endocrine Therapy +/- Chemotherapy In Patients With 1-3 Positive Nodes, Hormone Receptor-Positive And Her2-Negative Breast Cancer With Recurrence Score (RS) Of 25 Or Less. Rxponder: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: S1007
Phase: III

S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer

[Complete title: Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: S1200
Phase: NA

Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer

[Complete title: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Lung-Map)]
Principal Investigator: Christina Baik
Study Number: S1400
Phase: II/III

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

[Complete title: Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: S1406
Phase: II

Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

[Complete title: An Open Label, Expanded Access Protocol Using 131I - Metaiodobenzylguanidine (131I-MIBG) Thearpy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma]
Principal Investigator: Julie Park, MD
Study Number: SC-4002

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

[Complete title: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC]
Principal Investigator: Todd Cooper
Study Number: TACL 2008-002
Phase: I

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

[Complete title: A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL]
Principal Investigator: Todd Cooper
Study Number: TACL 2009-003
Phase: Pilot

A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

[Complete title: A Multicenter, Open-label Single-arm Study of YONDELIS® (trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment]
Principal Investigator: Edward Kim
Study Number: 20051530
Phase: III

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

[Complete title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin’s Lymphoma (NHL)]
Principal Investigator: Ajay Gopal, MD
Study Number: 20110654
Phase: I

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

[Complete title: A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patient with Unresectable Hepatocellular Carcinoma (HCC)]
Principal Investigator: William Harris
Study Number: 20111617
Phase: III

A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

[Complete title: A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects with Advanced Non-Small Cell Lung Cancer and BRAF Mutations]
Principal Investigator: Christina Baik
Study Number: 20111838
Phase: II

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

[Complete title: A Multi-arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Subjects with Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)]
Principal Investigator: Laura Chow
Study Number: 20120011
Phase: I

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

[Complete title: A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Christina Baik
Study Number: 20120636
Phase: I/II

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

[Complete title: A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP30862 in Patients with Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20121064
Phase: I

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

[Complete title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30-Positive Mature T-cell Lymphomas]
Principal Investigator: Andrei Shustov, MD
Study Number: 20121207
Phase: III

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

[Complete title: A Randomized, Open-Label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 20121311
Phase: III

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

[Complete title: Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell LymphomaOpen-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma]
Principal Investigator: Andrei Shustov, MD
Study Number: 20121464
Phase: III

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1)

[Complete title: An Exploratory Study of the Biologic Effects of Nivolumab and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20122036
Phase: I

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy

[Complete title: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy]
Principal Investigator: William Harris
Study Number: 20122073
Phase: III

A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

[Complete title: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS 9973 in Subjects with Relapsed or Refractory Hematologic Malignancies]
Principal Investigator: Andrei Shustov, MD
Study Number: 20122094
Phase: II

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

[Complete title: Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy.]
Principal Investigator: Evan Yu, MD
Study Number: 20122140
Phase: II

STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer

[Complete title: Steam (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent and Sequential) vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20130142
Phase: II

A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

[Complete title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20130328
Phase: III

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

[Complete title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib]
Principal Investigator: William Harris
Study Number: 20130857
Phase: III

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

[Complete title: The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20130917
Phase: II

A Safety Study of SGN-LIV1A in Breast Cancer Patients

[Complete title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer]
Principal Investigator: Jennifer Specht, MD
Study Number: 20131069
Phase: I

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

[Complete title: An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma]
Principal Investigator: Marc Chamberlain, MD
Study Number: 20131088
Phase: I/II

AZD8186 First Time In Patient Ascending Dose Study

[Complete title: A Phase 1, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZ8186 in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC), Squamoous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-Deficient Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZ8186 with Prospectively-validated PTEN-deficient Tumors]
Principal Investigator: Tia Higano, MD
Study Number: 20131275
Phase: I

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

[Complete title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 20131299
Phase: III

A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH"

[Complete title: A Phase II, Multicenter, Single-Arm study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell lung Cancer]
Principal Investigator: Laura Chow
Study Number: 20131756
Phase: II

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (D4190C00006)

[Complete title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736, in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer]
Principal Investigator: Sylvia Lee, MD
Study Number: 20131955
Phase: I/II

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

[Complete title: A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer]
Principal Investigator: Hannah Linden, MD
Study Number: 20132066
Phase: II

MSB0010718C in Solid Tumors

[Complete title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications]
Principal Investigator: Nora Disis, MD
Study Number: 20132079
Phase: I

An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

[Complete title: An Open-Label, Extension (Rollover) Study Of Vemurafenib in Patients with BRAFV600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol.]
Principal Investigator: John Thompson, MD
Study Number: 20132215
Phase: III

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

[Complete title: Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia]
Principal Investigator: Edward Libby
Study Number: 20132221
Phase: I/II

Safety Study of Anti-LAG-3 in CLL, HL and NHL

[Complete title: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas]
Principal Investigator: Ajay Gopal, MD
Study Number: 20132238
Phase: I

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

[Complete title: A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20132322
Phase: I

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

[Complete title: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer]
Principal Investigator: Evan Yu, MD
Study Number: 20140069
Phase: I

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

[Complete title: A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)]
Principal Investigator: Christina Baik
Study Number: 20140088
Phase: II

Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

[Complete title: A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects with Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)]
Principal Investigator: John Thompson, MD
Study Number: 20140404
Phase: I/II

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)

[Complete title: A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of gefitinib in Combination with MEDI4736 (anti PD-L1) in Subjects with Non-Small Cell Lung Cancer(NSCLC)]
Principal Investigator: Laura Chow
Study Number: 20140532
Phase: I

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

[Complete title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non–Small Cell Lung Cancer That Is Stage IIIB With Pleural/Pericardial Effusion, Stage IV, or Recurrent.]
Principal Investigator: Christina Baik
Study Number: 20140650
Phase: II

A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer

[Complete title: A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzmab Plus Pertuzumab Plus Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer]
Principal Investigator: V.K. Gadi, MD, PhD
Study Number: 20140740
Phase: III

A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies

[Complete title: A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of AMP-514 in Combination with MEDI4736 in Subjects with Advanced Malignancies]
Principal Investigator: Laura Chow
Study Number: 20140775
Phase: I

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

[Complete title: A Randomized Open-Label Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination with Abiraterone Acetate or Enzalutamide in Subjects with Castration-Resistant Prostate Cancer (CRPC) Who Have Bone Metastases]
Principal Investigator: Tia Higano, MD
Study Number: 20140832
Phase: II

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) (apact)

[Complete title: A Phase 3, Multicenter, Open-label, Randomized Study of nab®-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma]
Principal Investigator: Gabriela Chiorean
Study Number: 20140859
Phase: III

A Study of the Efficacy and Safety of Nivolumab vs Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients at Different Stages of Treatment (CheckMate 143)

[Complete title: A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)]
Principal Investigator: Marc Chamberlain, MD
Study Number: 20140894
Phase: II

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

[Complete title: A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin®) in Patients with Solid Tumors]
Principal Investigator: Barbara Ann Goff, MD
Study Number: 20140982
Phase: I

Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL

[Complete title: A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20141037
Phase: II

MSB0010718C in Subjects With Merkel Cell Carcinoma

[Complete title: A Phase II, open-label, multicenter trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel cell carcinoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20141039
Phase: II

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

[Complete title: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)]
Principal Investigator: Gabriela Chiorean
Study Number: 20141052
Phase: III

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

[Complete title: A Phase 1, Dose Escalation Study of PF-06664178 in Patients with Locally Advanced or Metastatic Solid Tumors]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20141074
Phase: I

Safety Study of SGN-CD70A in Cancer Patients

[Complete title: A Phase 1 trial of SGN-CD70A in patients with CD70-positive malignancies]
Principal Investigator: John Thompson, MD
Study Number: 20141105
Phase: I

A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors

[Complete title: A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent To Patients with Locally Advanced Or Metastatic Solid Tumors]
Principal Investigator: Laura Chow
Study Number: 20141118
Phase: I

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas (STARRS)

[Complete title: A Phase 2, Open-label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Squamous Cell Carcinoma of Head and Neck, Lung, or Esophagus]
Principal Investigator: Tina Rodriguez
Study Number: 20141119
Phase: II

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

[Complete title: Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/ B-Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy after Failing First-Line Therapy with FOLFIRINOX (or FOLFOX)]
Principal Investigator: Gabriela Chiorean
Study Number: 20141153
Phase: I

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)

[Complete title: A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 20141233
Phase: I/II

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

[Complete title: A Phase 1B Study of the 4-1BB Agonist PF-05082566 in Combination with the PD-1 Inhibitor MK-3475 in Patients with Advanced Solid Tumors]
Principal Investigator: Laura Chow
Study Number: 20141293
Phase: I

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide (UPWARD)

[Complete title: A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure]
Principal Investigator: Evan Yu, MD
Study Number: 20141311
Phase: IV

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms (ERA 223)

[Complete title: A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)]
Principal Investigator: Tia Higano, MD
Study Number: 20141419
Phase: III

Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)

[Complete title: A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20141655
Phase: I/II

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

[Complete title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma]
Principal Investigator: Scott Tykodi, MD
Study Number: 20141772
Phase: III

A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

[Complete title: An Open-Label, Phase I Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer]
Principal Investigator: Hannah Linden, MD
Study Number: 20141791
Phase: I

A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

[Complete title: A Phase 1 Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer]
Principal Investigator: Laura Chow
Study Number: 20141860
Phase: I

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

[Complete title: A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA]
Principal Investigator: Edward Libby
Study Number: 20142069
Phase: I

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

[Complete title: A Phase 1 Study of ADI-PEG 20 Plus Sorafenib in Subjects WithAdvanced Hepatocellular Carcinoma (HCC)]
Principal Investigator: William Harris
Study Number: 20142070
Phase: I

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

[Complete title: TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Christina Baik
Study Number: 20142085
Phase: II

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

[Complete title: Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects with Advanced Malignancies]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20142263
Phase: I

A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

[Complete title: A Phase II, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients with HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received at Least One Prior Chemotherapy Regimen]
Principal Investigator: Christina Baik
Study Number: 20142268
Phase: II

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Posivie Solid Tumors

[Complete title: Phase 1, Two-Part, Multiple Ascending Dose Study of Anti-HER2 Fcab FS102 in Breast, Gastric, and Other Solid Tumors]
Principal Investigator: Gabriela Chiorean
Study Number: 20142312
Phase: I

ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies

[Complete title: A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects with B-cell Malignancies]
Principal Investigator: Stephen Smith
Study Number: 20142444
Phase: I/II

Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer

[Complete title: A Phase I Study of ES414 In Patients with Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20142613
Phase: I

A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors

[Complete title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC), MELANOMA, CLEAR CELL RENAL CELL CARCINOMA (RCC) OR SQUAMOUS CELL HEAD AND NECK CANCER (SCCHN)]
Principal Investigator: John Thompson, MD
Study Number: 20150061
Phase: I

An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma

[Complete title: An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma]
Principal Investigator: Stephen Smith
Study Number: 20150224
Phase: II

Safety Study of SEA-CD40 in Cancer Patients

[Complete title: A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies]
Principal Investigator: Andrew Coveler, MD
Study Number: 20150420
Phase: I

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

[Complete title: A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20150466
Phase: I

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

[Complete title: Phase 1/2 Open-Label Study of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) in Patients with Advanced Epidermal Growth Factor Receptor Mutant (DEL 19 OR L858R +/- T790M) Non-Small Cell Lung Cancer]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 20150645
Phase: I/II

The Vital Amyloidosis Study, a Phase 3, Multicenter Efficacy and Safety Study of NEOD001

[Complete title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled. 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis]
Principal Investigator: Edward Libby
Study Number: 20150681
Phase: III

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

[Complete title: An Open-label, Multi-Center, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared with Bendamustine + GA101 (RO5072759) in Patients with Rituximab-Refractory, Indolent Non-Hodgkin’s Lymphoma (NHL) Genentech Inc. / Protocol GA04753g]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2388.00
Phase: III

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

[Complete title: A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia-2 (CMML-2), Myelodysplasic Syndrome Having Failed Hypomethylating Treatment (MDS) and High-Risk Myelofibrosis (MF)]
Principal Investigator: Bart Scott, MD
Study Number: 2513.00
Phase: I

Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

[Complete title: Head to Head Trial of Ofatumumab versus Rituximab – A Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy]
Principal Investigator: Benjamin Greer, MD
Study Number: 2522.00
Phase: III

Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma (11-MM-01)

[Complete title: A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone Prior to Autologous Stem Cell Transplant in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2599.00
Phase: I

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

[Complete title: A Phase 1/II, Open-Label, Multicenter Study of ACY-1215 in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma]
Principal Investigator: Edward Libby
Study Number: 2600.00
Phase: I

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

[Complete title: A Study Evaluating BPX-501 T cells and AP1903 for Prevention of GVHD after HLA-Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2615.00
Phase: I/II

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

[Complete title: A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse]
Principal Investigator: Roland Walter, MD
Study Number: 2616.00
Phase: I

tudy to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

[Complete title: Phase III Randomized Observer –Blind Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals’ Herpes Zoster Vaccine GSK1437173A]
Principal Investigator: Michael Boeckh, MD
Study Number: 2635.00
Phase: III

A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma

[Complete title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980s) in combination with rituximab or polatuzumab vedotin (DCDS4501a) in combination with rituximab and a non-randomized phase Ib/II evaluation of polatuzumab vedotin in combination with obtinutuzumab in patients with relapsed or refractory B-cell non-Hodgkins's lymphoma]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2649.00
Phase: II

ety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

[Complete title: A Phase1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2653.00
Phase: I

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer (HALO-109-202)

[Complete title: A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects with Stage IV Previously Untreated Pancreatic Cancer (WIRB HALO-109-202)]
Principal Investigator: Sunil Hingorani, MD, PhD
Study Number: 2687.00
Phase: II

A Safety Study of SGN-CD33A in AML Patients

[Complete title: A Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia]
Principal Investigator: Roland Walter, MD
Study Number: 2690.00
Phase: I

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)

[Complete title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)]
Principal Investigator: Michael Boeckh, MD
Study Number: 2707.00
Phase: III

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes

[Complete title: A Phase 1/2, Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation]
Principal Investigator: Bart Scott, MD
Study Number: 2709.00
Phase: I/II

A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients

[Complete title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients (CMX001-301)]
Principal Investigator: Michael Boeckh, MD
Study Number: 2718.00
Phase: III

Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

[Complete title: A Phase 1/2 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hematological Malignancies]
Principal Investigator: Bill Bensinger, MD
Study Number: 2724.00
Phase: I

Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer

[Complete title: A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 7248
Phase: II

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)

[Complete title: A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy]
Principal Investigator: William Harris
Study Number: 7627
Phase: III

Trial of pIL-12 Electroporation Malignant Melanoma (IL12MEL)

[Complete title: A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 7703
Phase: II

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR)

[Complete title: A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute - Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 8028
Phase: III

A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)

[Complete title: A Phase III Double-blinded, Placebo Controlled Study of XilonixTM for Improving Survival in Metastatic Colorectal Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 8041
Phase: III

Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts

[Complete title: Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women with Dense Breasts]
Principal Investigator: Constance Lehman, MD, PhD
Study Number: 8159
Phase: NA

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML (RADIUS)

[Complete title: A Phase II, Randomized Trial of Standard of Care, with or without Midostaurin to Prevent Relapse following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia]
Principal Investigator: Bart Scott, MD
Study Number: 9037
Phase: II

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

[Complete title: A Phase 1B/2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (Ricolinostat) in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma]
Principal Investigator: Edward Libby
Study Number: 9056
Phase: I/II

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

[Complete title: A Phase 3, Randomized, Double-Blind Active-Controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)]
Principal Investigator: Joachim Deeg, MD
Study Number: 9061
Phase: III

A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

[Complete title: A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 20140453]
Principal Investigator: Seth Pollack
Study Number: 9079
Phase: I

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

[Complete title: A Phase II, Randomized, Double-blind, Placebo-controlled study to examine the effects of DAS181 in immunocompromised subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen]
Principal Investigator: Michael Boeckh, MD
Study Number: 9108
Phase: II

A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

[Complete title: A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered with Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma F. Hoffmann-LaRoche/GO29383]
Principal Investigator: Brian Till, MD
Study Number: 9162
Phase: I

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

[Complete title: Phase 2, Randomized, Double-Blind, Placebo-controlled Study of Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Phase in Subjects with Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia]
Principal Investigator: Joachim Deeg, MD
Study Number: 9185
Phase: I/II

A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3)

[Complete title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer]
Principal Investigator: Elizabeth Swisher, MD
Study Number: 9191
Phase: III

GS-5806 in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

[Complete title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract]
Principal Investigator: Michael Boeckh, MD
Study Number: 9208
Phase: II

GS-5806 in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

[Complete title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract]
Principal Investigator: Alpana Waghmare
Study Number: 9212
Phase: II

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)

[Complete title: A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies]
Principal Investigator: Bill Bensinger, MD
Study Number: 9219
Phase: I/II

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

[Complete title: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma]
Principal Investigator: Damian Green, MD
Study Number: 9229
Phase: III

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

[Complete title: A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML)]
Principal Investigator: Roland Walter, MD
Study Number: 9233
Phase: I

MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

[Complete title: A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients]
Principal Investigator: Maggie Green
Study Number: 9235
Phase: III

A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)

[Complete title: A Phase 1/2 Study of ABT-199 in Combination with Low-Dose Cytarabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are >= 65 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy]
Principal Investigator: Roland Walter, MD
Study Number: 9237
Phase: I/II

A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

[Complete title: A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1]
Principal Investigator: Seth Pollack
Study Number: 9290
Phase: I

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

[Complete title: A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease]
Principal Investigator: Mary Flowers, MD
Study Number: 9326
Phase: I/II

Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection (CMX001 Adv)

[Complete title: A Phase 3, Open-label, Multicenter Study of the Safety/Tolerability and Efficacy of Brincidofovir (CMX001) for the Prevention of Adenovirus (AdV) Disease in Subjects with Asymptomatic AdV Infection at Risk of Progression and for the Treatment of Subjects with Localized or Disseminated AdV Disease]
Principal Investigator: Steven Pergam, MD
Study Number: 9371
Phase: III

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

[Complete title: ADVL1322, A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors]
Principal Investigator: Julie Park, MD
Study Number: ADVL1322
Phase: II

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

[Complete title: A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer]
Principal Investigator: Elizabeth Swisher, MD
Study Number: CO-338-017
Phase: II

Outcomes in Reproduction for Childhood Survivors (ORCAS-Cisplatin): A Multi Site Pilot Study
Principal Investigator: Margarett Shnorhavorian
Study Number: ORCAS-2
Phase: NA

A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

[Complete title: SC-2020, A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin]
Principal Investigator: Rebecca Gardner, MD
Study Number: SC-2020
Phase: II

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

[Complete title: Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors]
Principal Investigator: Sarah Leary
Study Number: SC-4003
Phase: I/II

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

[Complete title: A Phase I Dose Escalation Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors including Tumors of the Central Nervous System]
Principal Investigator: Sarah Leary
Study Number: SC-8002
Phase: I

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

[Complete title: A Phase 1 Dose-Escalation And Expansion Study Of BLZ-100 In Pediatric Subjects With Primary Central Nervous System Tumors]
Principal Investigator: Sarah Leary
Study Number: SC-9009
Phase: I

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials